Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis

Immune checkpoint inhibitors (ICI) such as Programmed cell Death 1 (PD-1) inhibitors have improved cancer treatment by enhancing the immune system's ability to target malignant cells. Their use is associated with immune-related adverse events (irAEs), including uveitis. The profile of pro-infla...

Full description

Saved in:
Bibliographic Details
Published in:BMC ophthalmology 2024-07, Vol.24 (1), p.312-10, Article 312
Main Authors: Brown, Aaron C, Quiroz, José, Parikh, Devayu A, Li, Yafeng, Ritzer, Lukas, Rosen, Richard, Deobhakta, Avnish
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
B cells
Cancer
Cancer therapies
Care and treatment
Cell death
Chemokines
Complications and side effects
Corticosteroids
Cytokines
Cytokines - metabolism
Drug Therapy
Granulocytes
Humans
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors - adverse effects
Immune system
Inflammation
Interferon
Kidney cancer
Ligands
Lung cancer
Lymphocytes
Melanoma
Metastasis
Monoclonal antibodies
PD-1 protein
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Proteins
Review
Skin cancer
Steroids
Tumor necrosis factor-TNF
Uveitis
Uveitis - chemically induced
Uveitis - drug therapy
Uveitis - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICI) such as Programmed cell Death 1 (PD-1) inhibitors have improved cancer treatment by enhancing the immune system's ability to target malignant cells. Their use is associated with immune-related adverse events (irAEs), including uveitis. The profile of pro-inflammatory cytokines underlying Anti-PD-1-induced uveitis shares significant overlap with that of non-infectious uveitis. Current corticosteroid treatments for uveitis while effective are fraught with vision threatening side effects. The cytokine profile in ICI-related uveitis has a large overlap with that of noninfectious uveitis, this overlap strongly supports the potential for therapy that activates the PD-1 axis in the eye to treat uveitis. Indeed, ICI related uveitis often resolves with cessation of the ICI, restoring the endogenous PD-1 axis. The potential benefit of targeting many pro-inflammatory cytokines via local PD-1 axis activation is mitigating ocular inflammation while minimizing adverse effects.
ISSN:1471-2415
1471-2415
DOI:10.1186/s12886-024-03575-7